Christopher DelOrefice - 31 Mar 2026 Form 4 Insider Report for Ulta Beauty, Inc. (ULTA)

Reporting relationship: Chief Financial Officer
Issuer ticker: ULTA
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 16:45:44 UTC
Prior SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Rene G. Casares, as attorney-in-fact for Christopher DelOrefice

Key filing fact

Christopher DelOrefice filed Form 4 for Ulta Beauty, Inc. (ULTA) on 02 Apr 2026.

Key facts

This page summarizes Christopher DelOrefice's Form 4 filing for Ulta Beauty, Inc. (ULTA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 16:45.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001881430 Primary reporting owner

DelOrefice Christopher

Relationship: Chief Financial Officer
Address: 1000 REMINGTON BLVD., SUITE 120, BOLINGBROOK
Signature: /s/ Rene G. Casares, as attorney-in-fact for Christopher DelOrefice
Signature date: 02 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ULTA transaction

Common Stock

Award

Transaction value
Shares: +4,219
Change %: +77%
Price: $0.000000^*
Shares after: 9,693
Date: 31 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ULTA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +14,363
Change %
Price: $0.000000^*
Shares after: 14,363
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,363
Exercise price: $522.71
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents grant of 4,219 shares of restricted stock, vesting 100% on March 15, 2029.

Footnote F2

The options, representing an initial right to purchase a total of 14,363 shares, vesting in 25% annual increments beginning March 15, 2027 and each anniversary thereafter through March 15, 2030.